AWM
REGN icon

Affinity Wealth Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Affinity Wealth Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-2,272
Closed -$1.44M – 82
2020
Q2 		$1.44M Buy
+2,272
New +$1.29M 1.81% 26

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $11.6B AUM 8.03% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Affinity Wealth Management's REGN Position: Q3 2020 in Review

Affinity Wealth Management sold out of Regeneron Pharmaceuticals (REGN) in Q3 2020, closing a stake of 2,272 shares — an estimated $1.44M sold.

Affinity Wealth Management first reported a position in REGN in Q2 2020 and held it in 1 quarter. The position peaked at $1.44M in Q2 2020. 907 funds tracked by Wall St. Rank hold REGN as of Q3 2020.

  • Affinity Wealth Management reported no remaining Regeneron Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Affinity Wealth Management sold 2,272 Regeneron Pharmaceuticals shares in Q3 2020, an estimated $1.44M.
  • Affinity Wealth Management first reported a position in Regeneron Pharmaceuticals in Q2 2020 and held it in 1 quarter.
  • Affinity Wealth Management's Regeneron Pharmaceuticals position peaked at $1.44M in Q2 2020.
  • 907 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2020.

Based on Affinity Wealth Management's 13F filing for Q3 2020, filed 16 Nov 2020.